statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its first quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 9, 2024...

Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) has earned a consensus recommendation of "Buy" from the five analysts that are covering the stock, MarketBeat reports. Five equities...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives $19.80 Consensus PT from Brokerages

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) was upgraded by StockNews.com from a "hold" rating to a "buy" rating in a research note issued on Friday.
IRWD has been the subject of a...

Ironwood Pharmaceuticals (NASDAQ:IRWD) Rating Increased to Buy at StockNews.com

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) and Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) are both medical companies, but which is the superior business? We will compare the...

Contrasting Ironwood Pharmaceuticals (NASDAQ:IRWD) & Rocket Pharmaceuticals (NASDAQ:RCKT)

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced positive, primary results up to Day 91 for its Phase II exploratory STARGAZE trial evaluating...

Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)

Capital One Financial analyst Tim Chiang maintained a Buy rating on Ironwood Pharma (IRWD Research Report) today and set a price target of $15.00...

Ironwood Pharmaceuticals: A Strong Buy on Promising Gastrointestinal Treatment Prospects and Market Expansion Opportunities

This is a signal that IRWD's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Ironwood Pharmaceuticals (IRWD, $8.62) RSI Indicator left the oversold zone on March 27, 2024

Ironwood Pharmaceuticals (IRWD, $8.41) RSI Indicator left the oversold zone on March 25, 2024

This is a Bullish indicator signaling IRWD's price could rise from here. Traders may explore going long the stock or buying call options...

Ironwood Pharmaceuticals (IRWD, $9.03) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 21, 2024

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD  Get Free Report) have been given a consensus recommendation of Buy by the five brokerages that are presently covering the...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Average Rating of "Buy" from Analysts

Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.

Volume	2.78M
52-Wk High	$15.70
52-Wk Low	$7.53

IRWD Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A

About

Feed

News

Sentiment

Earnings

Fundamentals